Featured Articles

  1. Early Product Characterization De-Risks Biologics Development 6/12/2019

    The relationship between physicochemical profile and biological activity — and how this relationship affects clinical performance — is key to informed decisions, accelerated development, and risk reduction.

  2. Innovating Upstream Manufacturing For The Next Wave Of Gene Therapies 3/4/2026

    Explore a streamlined approach to transient AAV production, including yield improvements across serotypes, key transfection parameters, and practical guidance for scaling processes.

  3. How A Specialized CDMO De-Risks Complex API Development 2/24/2026

    Rising API complexity and AI-driven chemistry require specialized CDMOs with technical expertise in hazardous or chiral synthesis to successfully navigate the transition to GMP manufacturing.

  4. A CDMO Is The Nexus Between Green Chemistry And Commercialization 2/24/2026

    Modern R&D transforms sustainability from an optional add-on into a strategic optimization tool, enhancing cost-efficiency, speed to market, and process intensification for drug developers.

  5. Why Reshoring Is An Essential Strategy For ADC Supply Chain Security 2/24/2026

    Biotechs reshoring their supply chains to Western regions to mitigate risk and improve reliability require experienced partners to effectively manage these complex transitions.

  6. A Comprehensive Solution For Adventitious Agent Testing 2/13/2026

    Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.

  7. Accelerate LNP Manufacturing With Automated Process Development 2/5/2026

    Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.

  8. Application Of A Dual Spiking Strategy In Viral Clearance Studies 2/3/2026

    Explore how an alternative spiking strategy can streamline viral clearance studies, reduce material demands, and maintain compliance while addressing the challenges posed by MLV and MMV.

  9. Selecting A CDMO For Custom Activated PEGs 1/27/2026

    Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.

  10. Integrated Solutions For Intensified mAb Processing 1/14/2026

    Intensify your mAb manufacturing with optimized media, advanced filtration, and real-time analytics. Learn how integrated upstream and downstream solutions boost productivity and reduce costs.